MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
June 23, 2005
Rich Smith
Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal. mark for My Articles similar articles
The Motley Fool
June 23, 2005
Stephen D. Simpson
Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects. mark for My Articles similar articles
The Motley Fool
June 23, 2005
Stephen D. Simpson
Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist? mark for My Articles similar articles
BusinessWeek
July 25, 2005
Gene G. Marcial
Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion. mark for My Articles similar articles
The Motley Fool
August 26, 2005
Stephen D. Simpson
Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note. mark for My Articles similar articles
The Motley Fool
December 21, 2006
Brian Lawler
Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout. mark for My Articles similar articles
The Motley Fool
December 21, 2006
Ryan Fuhrmann
Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space. mark for My Articles similar articles
The Motley Fool
August 22, 2005
Stephen D. Simpson
Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares. mark for My Articles similar articles
The Motley Fool
January 31, 2005
Stephen D. Simpson
Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break. mark for My Articles similar articles
The Motley Fool
February 21, 2006
Rick Aristotle Munarriz
Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes. mark for My Articles similar articles
The Motley Fool
January 25, 2005
Stephen D. Simpson
Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today. mark for My Articles similar articles
The Motley Fool
December 21, 2006
Ryan Fuhrmann
Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better. mark for My Articles similar articles
The Motley Fool
September 18, 2007
Brian Orelli
New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug. mark for My Articles similar articles
The Motley Fool
July 8, 2010
Brian Orelli
Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy. mark for My Articles similar articles
The Motley Fool
December 21, 2006
Brian Lawler
Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments. mark for My Articles similar articles
The Motley Fool
September 7, 2007
Billy Fisher
Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively. mark for My Articles similar articles
The Motley Fool
October 23, 2007
Brian Orelli
Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter. mark for My Articles similar articles
The Motley Fool
April 17, 2007
Brian Lawler
Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance. mark for My Articles similar articles
Chemistry World
March 13, 2007
Vioxx Trial Blow for Merck A jury has awarded $47.5 million to an Idaho man after finding that the anti-inflammatory drug Vioxx, made by Merck and Co., Inc., contributed to his heart attack. mark for My Articles similar articles
The Motley Fool
October 23, 2006
Brian Lawler
Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount. mark for My Articles similar articles
The Motley Fool
January 31, 2007
Brian Lawler
Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 4, 2004
Mathew Emmert
Got Merck? The pharmaceutical's investors can't seem to catch a break. mark for My Articles similar articles
The Motley Fool
May 21, 2008
Brian Orelli
OK, Last Vioxx Settlement, Honest! What's another $58 million when Merck's already forking over $4.85 billion? mark for My Articles similar articles
The Motley Fool
November 25, 2011
Dan Caplinger
Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs. mark for My Articles similar articles
The Motley Fool
February 23, 2005
Stephen D. Simpson
Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector. mark for My Articles similar articles
The Motley Fool
October 24, 2005
Stephen D. Simpson
Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors. mark for My Articles similar articles
The Motley Fool
November 15, 2004
Mathew Emmert
Merck's Silver Lining The government joins the plethora of lawsuit filers, but Merck will survive. Still, the stock remains appropriate for only those investors with a high tolerance for risk and a long-term time horizon. mark for My Articles similar articles
The Motley Fool
January 25, 2006
Tim Hanson
Find the Silver Lining Falling stock prices don't have to be all bad news. While market drops can test your will, it's always best to keep a level head. mark for My Articles similar articles
The Motley Fool
February 22, 2005
Charly Travers
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. mark for My Articles similar articles
The Motley Fool
July 24, 2006
Stephen D. Simpson
Wait for a Bad Day at Merck Merck has value as a going concern, but investors should wait for some bad news to make the stock cheaper. mark for My Articles similar articles
BusinessWeek
September 5, 2005
Amy Barrett
The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come mark for My Articles similar articles
The Motley Fool
January 27, 2004
Jeff Hwang
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. mark for My Articles similar articles
The Motley Fool
August 2, 2007
Brian Orelli
98 Lawsuits Down, About 15,000 To Go Merck's Vioxx caseload just got a little smaller, when an appellate court ruled that 98 people from England and Wales could not sue in the U.S. Shares are up on the news. mark for My Articles similar articles
The Motley Fool
February 24, 2011
Jordan DiPietro
Should You Retire With Merck? Is Merck a good choice for a retirement portfolio? mark for My Articles similar articles
The Motley Fool
November 29, 2010
Brian Orelli
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain. mark for My Articles similar articles
The Motley Fool
May 30, 2008
Brian Orelli
For Merck, Hindsight Hurts Even after dragging its feet for years, one has to wonder if Merck settled the Vioxx cases a little too quickly? mark for My Articles similar articles
Bio-IT World
December 15, 2004
Kevin Davies
Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first. mark for My Articles similar articles
The Motley Fool
September 1, 2009
Brian Orelli
Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company. mark for My Articles similar articles
The Motley Fool
July 18, 2008
Brian Orelli
Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news. mark for My Articles similar articles
The Motley Fool
March 18, 2009
Brian Orelli
Merck Pummels Pfizer One of these acquisitions is not like the other. mark for My Articles similar articles
The Motley Fool
September 11, 2008
Brian Orelli
Vive le Vioxx Lawsuit Just when Merck thought it was finally done with lawsuits pertaining to Vioxx, it's gotten pulled back in. mark for My Articles similar articles
The Motley Fool
April 11, 2007
Billy Fisher
A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders. mark for My Articles similar articles
The Motley Fool
October 11, 2010
Brian Orelli
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... mark for My Articles similar articles
The Motley Fool
October 21, 2004
Brian Gorman
Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight. mark for My Articles similar articles
BusinessWeek
December 5, 2005
Michael Orey
Presto: A New Vioxx Liability Estimate! Why analysts' reports shift wildly with every twist in litigation against Merck. mark for My Articles similar articles
The Motley Fool
November 25, 2009
Brian Orelli
A Schizophrenic Move by Merck? Issue $29 billion in shares, buy back $3 billion. Say what? Merck increased its share count by almost 45% to pay for the acquisition of Schering-Plough. Now it's planning to buy some of that stock back. mark for My Articles similar articles
The Motley Fool
September 30, 2004
W. D. Crotty
Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment. mark for My Articles similar articles
The Motley Fool
December 13, 2005
Rich Duprey
Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors. mark for My Articles similar articles
The Motley Fool
May 12, 2010
Brian Orelli
Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong. mark for My Articles similar articles
The Motley Fool
August 30, 2010
Brian Orelli
It's a Blockbuster ... Maybe On the surface, sanofi-aventis' oral multiple sclerosis drug teriflunomide looks like a hit. But below the surface? mark for My Articles similar articles